May 18, 2022
Chimerix Sells Smallpox Countermeasure to Emergent to Focus on Rare Cancer Drug Development
Read More
May 17, 2022
Ultragenyx Acquires Global Rights to Abeona Gene Therapy for Sanfilippo Syndrome
Read More
May 16, 2022
KemPharm to Acquire Orphazyme, Expanding its Rare CNS Diseases Pipeline
Read More
May 13, 2022
BridgeBio Sells Rare Pediatric Disease Priority Review Voucher for $110 Million, Defers Debt Payment
Read More
May 12, 2022
BridgeBio Licenses SHP2 Inhibitor to Bristol Myers Squibb in Oncology
Read More
May 10, 2022
Novo Nordisk and Flagship Pioneering Enter Collaboration to Create Portfolio of Transformational Medicines
Read More
May 10, 2022
Cortexyme to Acquire Novosteo, Expanding Pipeline into Rare Skeletal Disease
Read More
May 10, 2022
Rallybio In-Licenses Preclinical Antibody Candidate from Sanofi Targeting Rare Blood Disorders
Read More
May 4, 2022
n-Lorem Foundation and Columbia University Establish ALS Initiative
Read More
May 2, 2022
AI Therapeutics Acquires Novel Cancer Drug Candidate for the Treatment of Rare Pediatric Cancers
Read More
April 29, 2022
Peak Bio to Go Public in Merger with Ignyte Acquisition SPAC
Read More
April 26, 2022
Adge Pharmaceuticals Enters Partnership with Cyan Bio for Rare Disease Therapy in Asia
Read More
Load More
X